医学
心脏病学
内科学
肥厚性心肌病
危险分层
心源性猝死
心室流出道梗阻
心室流出道
心力衰竭
猝死
前瞻性队列研究
心肌病
观察研究
射血分数
心电图
试验预测值
药物治疗
心脏病
窦性心律
弗雷明翰风险评分
队列
作者
M Silveira Ramos,R Esculudes Dos Santos Ferrao Gomes,R Lima,D Correia,S Maltes,Tânia Laranjeira,G Cunha,C Aguiar,B M Rocha
标识
DOI:10.1093/ejhf/xuag193.1195
摘要
Abstract Background Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death (SCD). Risk stratification may be performed using the HCM Risk-SCD score, which has been validated in cohorts of patients treated with first-line medical therapy (beta-blockers or calcium channel blockers). Mavacamten, a novel selective cardiac myosin inhibitor, has been shown to reduce left ventricular outflow tract obstruction (LVOTO) and to promote reverse remodeling. Its influence on the estimated HCM Risk-SCD score, which incorporates echocardiographic parameters that may change with therapy, remains unclear. Objective To assess hypothetical changes in the estimated HCM Risk-SCD score in patients with obstructive HCM treated with mavacamten. Methods We conducted a prospective observational study including all patients with HCM treated with mavacamten who had been on a stable dose for at least 3 months. Clinical data and transthoracic echocardiograms were reviewed to collect maximal wall thickness (MWT), left atrial diameter (LAD), and maximal LVOTO. The HCM Risk-SCD score was calculated using the ESC online tool. Comparisons were assessed using the Wilcoxon signed-rank test. Results Forty patients were included [58% male; median age 62 (61–71) years and follow-up 7 (3–12) months]. Echocardiographic parameters improved significantly in comparison to baseline, with reductions in maximal LVOTO [84 (68–129) vs. 5 (0–39) mmHg; p<0.001], MWT [18 (16–20) vs. 15 (14–18) mm; p<0.001], and LAD [43 (39–47) vs. 40 (36–44) mm; p=0.008]. Mavacamten was associated with a significant reduction in the HCM Risk-SCD score, decreasing from 2.4 (1.7–4.7) to 1.5 (1.1–2.6) %, corresponding to an absolute change of −0.9 (−2.0 to −0.5) % and a relative reduction of −40 (−52 to −26) % (p<0.001) (central figure). At baseline, four patients had a high estimated 5-year SCD risk (>6%) – all of whom had an implantable cardioverter-defibrillator. During follow-up, three were reclassified in the low-risk category (<4%), while one remained in the high-risk group. No patient transitioned into a higher risk category after treatment. Per-patient decomposition of the HCM Risk-SCD reduction showed that most of the improvement was driven by changes in LVOTO (median −0.52%), with smaller contributions from MWT (−0.29%) and LAD (−0.08%). Conclusion Mavacamten was associated with a significant reduction in the estimated HCM Risk-SCD score. Whether this improvement translates into a true reduction in the 5-year SCD incidence remains uncertain. External validation in large multicenter cohorts with long-term follow-up is required to determine whether the decrease in the hypothetical risk corresponds to reduced mortality.Central figureFor image description, please refer to the figure legend and surrounding text.
科研通智能强力驱动
Strongly Powered by AbleSci AI